Target intelligence / Profile preview

Potassium voltage-gated channel modifier subfamily G member 4 (KCNG4)

Target
KCNG4
Molecular classification
Ion channel, Voltage-gated potassium channel (Kv) modulatory subunit, Channel regulatory subunit (does not form active channels alone, acts as modifier)
01

Overview

Potassium voltage-gated channel modifier subfamily G member 4 (KCNG4) is a regulatory subunit of the voltage-gated potassium (Kv) channels, specifically associated with the modulation of heterotetrameric channel complexes such as those formed with KCNB1 (Kv2.1). KCNG4 does not form functional channels on its own but alters channel properties—such as activation kinetics and voltage dependence—when coexpressed with pore-forming Kv alpha subunits. It is primarily expressed in the brain and is associated with physiological processes like neuronal excitability, neurotransmitter release, and other potassium channel-related activities. Mutations or dysregulation in KCNG4 have been implicated in congenital stationary night blindness and distal arthrogryposis. No direct KDNG4-selective drugs are known, and its therapeutic relevance is primarily as a modulator of complex channel assemblies rather than as an independent drug target.

Other names
Voltage-gated potassium channel regulatory subunit KCNG4Kv6.4Kv6.3 (sometimes used, but note: Kv6.3 is more specifically KCNG3)Potassium voltage-gated channel subfamily G member 4Voltage-gated potassium channel subunit Kv6.3 (but see above comment)Voltage-gated potassium channel subunit Kv6.4KCNG3 (sometimes confused, but should refer to a different gene)Potassium channel, voltage-gated, modifier subfamily G, member 4
02

Biological functions

Regulation of membrane potentialModulation of neuronal excitabilityRegulation of neurotransmitter releaseModulation of potassium ion transmembrane transportRegulation of action potential repolarization
03

Disease associations

Congenital stationary night blindness, type 1DDistal arthrogryposis, type 1AMay play a role in neurological disorders (based on related pathway/disease implication)
04

Safety considerations

Modulation of potassium channels can risk arrhythmia and neurological side effects if the channels are involved in heart and brain functionSince KCNG4 alone does not form functional channels, direct targeting is less likely to yield a distinct safety profile compared to alpha-subunit channel blockers or openers.

Beyond the preview

Go deeper on Potassium voltage-gated channel modifier subfamily G member 4 (KCNG4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Potassium voltage-gated channel modifier subfamily G member 4 (KCNG4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call